Securian Asset Management Inc. Decreases Stock Holdings in Revvity, Inc. (NYSE:RVTY)

Securian Asset Management Inc. lowered its stake in shares of Revvity, Inc. (NYSE:RVTY) by 4.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,449 shares of the company’s stock after selling 302 shares during the quarter. Securian Asset Management Inc.’s holdings in Revvity were worth $720,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Janus Henderson Group PLC increased its position in shares of Revvity by 1.7% during the third quarter. Janus Henderson Group PLC now owns 6,335,302 shares of the company’s stock valued at $809,332,000 after buying an additional 108,401 shares during the period. State Street Corp increased its position in shares of Revvity by 0.3% during the third quarter. State Street Corp now owns 5,180,169 shares of the company’s stock valued at $661,767,000 after buying an additional 17,832 shares during the period. Geode Capital Management LLC increased its position in shares of Revvity by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,863,793 shares of the company’s stock valued at $364,569,000 after buying an additional 25,078 shares during the period. EdgePoint Investment Group Inc. increased its position in shares of Revvity by 34.6% during the third quarter. EdgePoint Investment Group Inc. now owns 2,685,775 shares of the company’s stock valued at $343,108,000 after buying an additional 690,534 shares during the period. Finally, RGM Capital LLC increased its position in shares of Revvity by 3.2% during the third quarter. RGM Capital LLC now owns 980,858 shares of the company’s stock valued at $125,305,000 after buying an additional 30,000 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Trading Up 1.6 %

Shares of NYSE RVTY opened at $112.13 on Monday. The firm’s 50 day moving average price is $117.01 and its 200-day moving average price is $117.93. The company has a market cap of $13.47 billion, a PE ratio of 50.74, a P/E/G ratio of 3.82 and a beta of 1.06. Revvity, Inc. has a 52-week low of $97.32 and a 52-week high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same quarter in the prior year, the business earned $1.25 EPS. On average, equities research analysts expect that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be given a dividend of $0.07 per share. The ex-dividend date is Thursday, April 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.25%. Revvity’s dividend payout ratio (DPR) is 12.67%.

Insider Activity at Revvity

In other Revvity news, insider Tajinder S. Vohra sold 5,492 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the transaction, the insider now directly owns 19,652 shares in the company, valued at approximately $2,295,550.12. This trade represents a 21.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the transaction, the insider now owns 33,400 shares in the company, valued at $4,232,782. The trade was a 31.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.60% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on RVTY. Bank of America upgraded shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price target on the stock in a research report on Friday, December 13th. KeyCorp upped their price objective on shares of Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Sanford C. Bernstein cut shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price objective on the stock. in a report on Friday, January 10th. Raymond James restated an “outperform” rating and issued a $145.00 price objective (up previously from $140.00) on shares of Revvity in a report on Monday, February 3rd. Finally, Barclays upped their price objective on shares of Revvity from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $136.25.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.